OSLO, Norway, Oct. 1, 2018 /PRNewswire/ -- Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that the Company presented at the following conference: 13th International Ad...
from PR Newswire: //https://ift.tt/2xQv11b
No comments:
Post a Comment